Julie V. Selkirk

SB‐224289–a novel selective (human) 5‐HT_1B receptor antagonist with negative intrinsic activity

Julie V. Selkirk, Claire M. Scott, M Ho et al. · British Journal of Pharmacology · 1998 · 124 citations · Full text

The Selective 5-HT_1BReceptor Inverse Agonist 1‘-Methyl-5-[[2‘-methyl-4‘- (5-methyl-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]carbonyl]-2,3,6,7-tetrahydro- spiro[furo[2,3-<i>f</i>]indole-3,4‘-piperidine] (SB-224289) Potently Blocks Terminal 5-HT Autoreceptor Function Both in Vitro and in Vivo

Laramie M. Gaster, Frank E. Blaney, Susannah Davies et al. · Journal of Medicinal Chemistry · 1998 · 81 citations · Full text

5‐HT_1A receptor agonist‐antagonist binding affinity difference as a measure of intrinsic activity in recombinant and native tissue systems

Jeannette M. Watson, L Collin, M Ho et al. · British Journal of Pharmacology · 2000 · 76 citations · Full text

Absorption, Metabolism, and Excretion, In Vitro Pharmacology, and Clinical Pharmacokinetics of Ozanimod, a Novel Sphingosine 1-Phosphate Receptor Modulator

Sekhar Surapaneni, Usha Yerramilli, April Bai et al. · Drug Metabolism and Disposition · 2021 · 70 citations · Full text

SB-236057, a selective 5-HT1B receptor inverse agonist, blocks the 5-HT human terminal autoreceptor

Derek N. Middlemiss, Manfred Göthert, Eberhard Schlicker et al. · European Journal of Pharmacology · 1999 · 39 citations

Signal Transduction, G Protein-coupled Receptor, Medicine +5